Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD)

Study Overview
=================
Brief Summary
-----------------
This study is conducted in the United States of America (USA). The aim of the study is to assess the minimal important difference (MID) of the TRIM-AGHD.

Official Title
-----------------
Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD)

Conditions
-----------------
Growth Hormone Disorder, Adult Growth Hormone Deficiency

Intervention / Treatment
-----------------
* Other: No treatment given


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Able to speak read and write English GHD (Growth Hormone Deficiency) treatment naïve which is defined as not being on a prescription treatment for their GHD currently and for at least 6 months Beginning a new prescription GHD treatment and expected to be on this treatment for GHD for a minimum of 6 months GHD of either one of the following criteria: a) Adult onset: subjects who have GHD, either alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or traumatic brain injury (TBI), b) Childhood Onset: Subjects who were growth hormone deficient during childhood as a result of congenital, genetic, acquired, or idiopathic causes Confirmed diagnosis of growth hormone deficiency (if a subject satisfies any one of the three following criteria): a) For the insulin tolerance test (ITT) or glucagon test both performed within the last five years: the validated cut-off for GHD in adults is a peak GH response of below 3.0 ng/mL (3 microg/L), b) For growth hormone releasing hormone (GHRH) +Arginine test performed within the last five years: for those subjects with a body mass index (BMI) below 25 kg/m^2, a peak GH below 11 ng/mL (microg /L); for BMI 25-30 kg/m^2, a peak GH below 8 ng/mL (8 microg/L); for BMI above 30 kg/m^2, a peak GH below 4 ng/mL 341 (4 microg/L ), c) Three or more pituitary hormone deficiencies at screening Informed consent obtained before any study-related activities. (Study-related activities are any procedure related to recording of data according to the protocol) Exclusion Criteria: Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation Patients who have been on a prescription medication for treatment of GHD in past 6 months Patients with a total Beck Depression Inventory II (BDI-II) score greater than 25 Females who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptive measures as required by local law or practice) Acute severe illness associated with weight loss in the last 6 months (defined as a loss of more than 5.0% total body weight) Active Cushings syndrome within the last 24 months Subject with overt diabetes mellitus Previous participation in this study

Ages Eligible for Study
-----------------
Minimum Age: 23 Years
Maximum Age: 79 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Survey<br> | Other: No treatment given<br>* Subject will only fill out a questionnaire when entering the non-interventional study<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in CGI (Clinician Global Impression Scale) |  | After the physician scheduled visits closest to week 8 and week 26 after initiation of treatment | 
| Changes in PGI (Patient Global Impression Scale) |  | After the physician scheduled visits closest to week 8 and week 26 after initiation of treatment |